The prophylactic use of tranexamic acid and aprotinin in orthotopic liver transplantation: A comparative study

2004 ◽  
Vol 10 (2) ◽  
pp. 279-284 ◽  
Author(s):  
Antonia Dalmau ◽  
Antoni Sabaté ◽  
Maylin Koo ◽  
Carlos Bartolomé ◽  
Antoni Rafecas ◽  
...  
1996 ◽  
Vol 85 (5) ◽  
pp. 1043-1048 ◽  
Author(s):  
John F. Boylan ◽  
John R. Klinck ◽  
Alan N. Sandler ◽  
Ramiro Arellano ◽  
Paul D. Greig ◽  
...  

Background Patients with end-stage liver disease frequently incur large-volume blood loss during liver transplantation associated with mechanical factors, preexisting coagulopathy, and intraoperative fibrinolysis. Methods Between April 1992 and May 1994, the authors of this double-blind, randomized, placebo-controlled study examined the effect of high-dose tranexamic acid (maximum of 20 g) on blood loss and blood product requirements in patients undergoing primary isolated orthotopic liver transplantation. Primary outcome measures were volume of blood loss (intraoperative blood loss and postoperative drainage) and erythrocyte, plasma, platelet, and cryoprecipitate use during surgery and the first 24 h of intensive care unit stay. Results Patients receiving tranexamic acid (n = 25) had less intraoperative blood loss (median, 4.3 l; interquartile range, 2.5 to 7.9; P = 0.006) compared with the placebo group (n = 20; median, 8 l; interquartile range, 5 to 15.8), and reduced intraoperative plasma, platelet, and cryoprecipitate requirements. Median perioperative erythrocyte use was 9 units (interquantile range, 4 to 14 units) in patients receiving tranexamic acid and 13 units (interquantile range, 7.5 to 31 units) in controls (P = 0.03). Total perioperative donor exposure was 20.5 units (interquantile range, 16 to 41 units) in patients receiving tranexamic acid and 43.5 units (interquantile range, 29.5 to 79 units) in controls (P = 0.003). Results for postoperative wound drainage were similar. Hospital stay and need for retransplantation were comparable in both groups. No patient in either group showed clinical evidence of hepatic artery or portal venous thrombosis within 1 month of transplantation. Conclusions High-dose tranexamic acid significantly reduces intraoperative blood loss and perioperative donor exposure in patients with end-stage parenchymal liver disease who are undergoing orthotopic liver transplantation, with marked reductions in platelet and cryoprecipitate requirements.


2017 ◽  
Vol 101 (7) ◽  
pp. 1658-1665 ◽  
Author(s):  
Adam Badenoch ◽  
Anand Sharma ◽  
Simon Gower ◽  
Markus Selzner ◽  
Coimbatore Srinivas ◽  
...  

2008 ◽  
Vol 55 (S1) ◽  
pp. 4746411-4746411
Author(s):  
Simon Gower ◽  
Coimbatore Srinivas ◽  
Reza Ghaffari ◽  
Nicholas Mitsakakis ◽  
Stuart McCluskey

1997 ◽  
Vol 85 (2) ◽  
pp. 281-285 ◽  
Author(s):  
Melanie Kaspar ◽  
Michael A. E. Ramsay ◽  
Ahn-Thuy Nguyen ◽  
Max Cogswell ◽  
George Hurst ◽  
...  

1999 ◽  
Vol 31 (1-2) ◽  
pp. 556-557 ◽  
Author(s):  
E Baldini ◽  
J Gugenheim ◽  
D Ouzan ◽  
N Katkhouda ◽  
J Mouiel

1998 ◽  
Vol 4 (2) ◽  
pp. 133-140 ◽  
Author(s):  
F. Xavier González ◽  
Juan C. Garcia-Valdecasas ◽  
Luis Grande ◽  
José L. Pacheco ◽  
Esteban Cugat ◽  
...  

1999 ◽  
Vol 31 (6) ◽  
pp. 2361-2362 ◽  
Author(s):  
A Dalmau ◽  
A Sabaté ◽  
F Acosta ◽  
L Garcia-Huete ◽  
M Koo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document